<DOC>
	<DOCNO>NCT03011892</DOCNO>
	<brief_summary>The purpose study establish efficacy strength INCB018424 cream daily ( QD ) twice daily ( BID ) subject atopic dermatitis compare vehicle cream BID .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy INCB018424 Phosphate Cream Applied Topically Adults With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Subjects diagnose atopic dermatitis define Hanifin Rajka criterion . Subjects history atopic dermatitis least 2 year . Subjects Investigator 's Global Assessment score 2 3 screening baseline . Subjects body surface area atopic dermatitis involvement , exclude face intertriginous area , 3 % 20 % screen baseline . Subjects agree discontinue agent use treat atopic dermatitis screen final followup visit . Subjects evidence active acute chronic infection . Use topical treatment atopic dermatitis ( bland emollient ) within 2 week baseline . Systemic immunosuppressive immunomodulating drug ( eg , oral injectable corticosteroid , methotrexate , cyclosporine , mycophenolate mofetil , azathioprine ) within 4 week 5 halflives baseline ( whichever longer ) . Subjects dermatologic disease besides atopic dermatitis whose presence treatment could complicate assessment disease ( eg , psoriasis ) . Subjects history disease besides dermatologic disorder ( eg , autoimmune disease ) take treatment could complicate assessment . Subjects cytopenias screening , define : Leukocytes &lt; 3.0 × 10^9/L . Neutrophils &lt; low limit normal . Hemoglobin &lt; 10 g/dL . Lymphocytes &lt; 0.8 × 10^9/L Platelets &lt; 100 × 10^9/L . Subjects severely impair liver function ( ChildPugh Class C ) endstage renal disease dialysis least 1 follow : Serum creatinine &gt; 1.5 mg/dL . Alanine aminotransferase aspartate aminotransferase ≥ 1.5 × upper limit normal . Subjects take potent systemic cytochrome P450 3A4 inhibitor fluconazole within 2 week 5 halflives , whichever longer , baseline visit ( topical agent limited systemic availability permit ) . Subjects previously receive Janus kinase inhibitor , systemic topical ( eg , ruxolitinib , tofacitinib , baricitinib , filgotinib , lestaurtinib , pacritinib ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>eczema</keyword>
	<keyword>pruritus</keyword>
	<keyword>Janus kinase ( JAK ) inhibitor</keyword>
</DOC>